Work

Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Emperial Trials

Year: 2020

Type: article

Source: Journal of Cardiac Failure

DOI: 10.1016/j.cardfail.2020.11.018

Authors: Stefan D. Anker, Piotr Ponikowski, Christoph Wanner, Egon Pfarr, Sibylle Hauske, Barbara Peil, Afshin Salsali, Ivana Ritter, Matias Nordaby, Audrey Koitka-Weber, Martina Brueckmann, Waheed Jamal, JoAnn Lindenfeld, William T. Abraham

Institutions: Charité – Universitätsmedizin Berlin, Wroclaw Medical University, Universitätsklinikum Würzburg, Boehringer Ingelheim (Germany), Heidelberg University, Boehringer Ingelheim (United States), Vanderbilt University Medical Center, The Ohio State University

Language: English

Topic: Heart Failure Treatment and Management

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3211103554

FWCI:

Cites:

Cited by:

Related to: 10